Results 171 to 180 of about 218,306 (297)

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

FREQUENCY OF MACROSCOPIC HAEMATURIA AFTER NATIVE RENAL BIOPSY USING FREE HANDS ULTRASOUND ASSISTED RENAL BIOPSY TECHNIQUE

, 2018
Background; Macroscopic haematuria is a commonly seen condition in the emergency department (ED), which has a variety of causes. This study was performed to ascertain frequency of macroscopic hematuria among patients undergoing native renal biopsy using ...
Batool, Zainab, Siddiqua, Ayesha, Ishaq, Misbha   +2 more
core  

Electron Microscopy in Renal Biopsy Interpretation: When and Why It Still Matters. [PDF]

Cureus
Qasim H, Hayajneh Z, Khattab K, Leoni MLG, Varrassi G.   +4 more
europepmc   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Clinical utility of BOLD-MRI in accurate diagnosis and prognostic evaluation of diabetic nephropathy: a prospective renal biopsy-based cohort study. [PDF]

Insights Imaging
Wang Q, Zhou S, Niu Y, Li C, Lyu Q, Chen P, Zhang X, Xie L, Shen W, Wang Y, Cao X, Cai G, Chen X, Wang H, Dong Z.   +14 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Membranous nephropathy in Kimura disease: A case report and literature review on renal biopsy findings. [PDF]

Clin Nephrol Case Stud
Murata M, Koga K, Yamaoka S, Hasebe M, Fukushima C, Omiya C, Yahata K.   +6 more
europepmc   +1 more source

From Metabolic Crisis to Molecular Classification: Multidisciplinary Management of Synchronous Endometrioid Ovarian and Endometrial Carcinomas With Massive Tumor Burden

Cancer Nexus, EarlyView.
Managing massive tumor burden in synchronous endometrioid carcinomas. The graphical abstract summarizes the clinical pathway from presentation with massive ascites, pleural effusion, and critical metabolic abnormalities to multidisciplinary stabilization, surgical management, integrated morphologic–molecular classification, and shared decision‐making ...
Anna Homeniuk, Leena Abdalla, Sharon Fitzgerald   +2 more
wiley   +1 more source

The value of renal biopsy in PLA₂R- antibody-positive patients with proteinuria: impact of additional pathologies on management and prognosis in a Chinese Cohort. [PDF]

Front Physiol
Lu S, Wang X, Wang X, Zhao M, Li H, Zhao Z.   +5 more
europepmc   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source